심부전 POC 및 LOC 디바이스 시장 : 검사 유형, 기술, 최종 용도별 - 세계 예측(2024-2032년)

Global Heart Failure POC and LOC Devices Market will showcase over 16.4% CAGR from 2024 to 2032, driven by improved healthcare infrastructure. According to the World Health Organization, global healthcare spending reached USD 8.3 trillion in 2022, reflecting a growing investment in advanced medical technologies.

As healthcare systems modernize, there is a greater emphasis on integrating advanced diagnostic technologies into routine practice. This development enhances accessibility and efficiency in detecting and managing heart failure. In both developed and emerging nations, investments in healthcare facilities and technology adoption facilitate broader availability of heart failure Point-of-Care POC and Laboratory-on-a-Chip LOC devices, enabling quicker and more accurate diagnoses. Such advancements improve patient outcomes by meeting the increasing demand for innovative diagnostic solutions, favoring the market outlook.

The heart failure POC and LOC devices industry is categorized based on technology, test type, end-use, and region.

The array-based systems segment will experience a significant CAGR during the forecast period, owing to their ability to provide high-throughput analysis in a single test. Array-based systems offer a multiplexed approach, enabling simultaneous measurement of multiple biomarkers associated with heart failure. This capability enhances diagnostic accuracy and efficiency, facilitating earlier detection and more effective management of the condition. As healthcare providers seek to optimize patient outcomes through more detailed and rapid diagnostics, the adoption of array-based systems in POC and LOC devices for heart failure is expected to increase.

The metabolomic testing segment will hold a noteworthy market share by 2032, because of the growing need for personalized medicine. This test provides detailed insights into metabolic profiles, which improve the precision of heart failure diagnosis and management. As healthcare increasingly shifts toward personalized approaches, the ability to perform rapid, detailed analyses at the point of care or through laboratory-on-a-chip technologies supports more tailored treatment plans. This shift towards precision medicine thrusts the demand for advanced diagnostic devices that quickly deliver comprehensive metabolic data, improving patient outcomes.

North America heart failure POC and LOC devices industry will witness a promising CAGR between 2024 and 2032, due to the focus on innovative healthcare solutions and high medical spending. North With a well-established healthcare infrastructure, there is a heightened awareness of heart disease and an emphasis on improving patient outcomes through early and accurate diagnosis. This growing emphasis on precision medicine, coupled with robust healthcare policies and funding, elevates the demand for advanced heart failure monitoring and diagnostic devices, fueling the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of heart failure and cardiovascular diseases
    • 3.2.1.2 Advancements in diagnostic technologies
    • 3.2.1.3 Government initiatives and healthcare policies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory landscape
    • 3.2.2.2 High cost associated with these devices
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Proteomic testing
• 5.3 Metabolomic testing
• 5.4 Genomic testing

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Microfluidics
• 6.3 Array-based systems
• 6.4 Other technologies

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Assisted living healthcare facilities
• 7.5 Homecare settings
• 7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abaxis, Inc.
• 9.2 Abbott Laboratories
• 9.3 Becton, Dickinson and Company
• 9.4 bioMerieux S.A.
• 9.5 BioTelemetry, Inc.
• 9.6 Danaher Corporation
• 9.7 F. Hoffmann-La Roche Ltd.
• 9.8 Instrumentation Laboratory
• 9.9 Jant Pharmacal Corporation
• 9.10 Masimo Corporation
• 9.11 Novartis AG
• 9.12 Quidel Corporation
• 9.13 Siemens Healthineers AG
• 9.14 Stryker Corporation
• 9.15 Trinity Biotech